Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Leases (2021 - 2025)

Krystal Biotech's Current Leases history spans 5 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Current Leases rose 45.52% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, up 45.52%, while the annual FY2025 figure was $1.8 million, 45.52% up from the prior year.
  • Current Leases for Q4 2025 was $1.8 million at Krystal Biotech, up from $1.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.8 million in Q4 2025 and bottomed at $934000.0 in Q2 2021.
  • The 5-year median for Current Leases is $1.4 million (2022), against an average of $1.4 million.
  • The largest annual shift saw Current Leases surged 51.71% in 2022 before it decreased 17.44% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.0 million in 2021, then skyrocketed by 49.95% to $1.6 million in 2022, then fell by 5.57% to $1.5 million in 2023, then fell by 17.44% to $1.2 million in 2024, then skyrocketed by 45.52% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Current Leases are $1.8 million (Q4 2025), $1.7 million (Q3 2025), and $1.6 million (Q2 2025).